37 results
Thumbnail

D2.127 - Rhinovirus Infection in Early Childhood and Risk of Asthma: A Two-Year Follow-Up Study

Thumbnail

D2.122 - Impact of Asthma on Outcomes after out-of-hospital cardiac arrest: A nationwide pathway-based analysis, 2013-2023

Thumbnail

D2.123 - Temporal Stability of Asthma-Related Out-of-Hospital Cardiac Arrest: A Nationwide SARIMA Analysis of Korean Data From 2013 to 2023

Thumbnail

D2.124 - Clinical Significance of Humoral Immunodeficiency in Patients with Severe Asthma

Thumbnail

D2.125 - When Severe Asthma Isn’t Asthma: A Case of Humoral Immunodeficiency With Suspicion of Lymphoproliferative Disease

Thumbnail

D2.126 - Analysis of Clinical Characteristics and Airway Morphological Structure Parameters in Patients with Bronchial Asthma Combined with Bronchiectasis

Thumbnail

D2.129 - Cardiac onset of EGPA in a postpartum woman: the importance of early diagnosis

Thumbnail

D2.130 - Dupilumab for asthma and chronic rhinosinusitis with or without nasal polyps : A Multi-Timepoint Real-World Analysis

Thumbnail

D2.131 - Application of a Neural Network Model for Predicting Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Comorbidities

Thumbnail

D2.132 - Prediction of Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Trigger Factors Using a Neural Network Model

Thumbnail

D2.133 - Assessment of growth pattern in wheezing children (3-12 years of age)

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial